ArticleJACC. Advances2026
Sex Differences in Pharmacologic Optimal Medical Therapy for Ischemic Heart Disease.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
backgroundDespite guideline recommendations for optimal medical therapy (OMT) for ischemic heart disease (IHD), sex disparities in pharmacologic treatment remain poorly characterized in recent years.
objectivesThe objective of the study was to examine sex differences in the use and trends of guideline-recommended OMT among adults with IHD in the United States from 2011 to 2020.
methodsWe performed a serial cross-sectional analysis using nationally representative data from the 2011 to 2020 National Health and Nutrition Examination Survey. Adults aged ≥18 years with self-reported IHD were included. OMT was defined as the use of antiplatelets, statins, β-blockers, and renin-angiotensin-aldosterone system inhibitors (RAASi). We examined differences in medication use by sex and evaluated temporal trends stratified by age (<50 vs ≥ 50 years), adjusting for sociodemographic and clinical factors.
resultsAmong 1,905 adults with IHD (40.6% women; mean age 65.4 years), women were significantly less likely than men to receive antiplatelets (68.0% vs 77.7%), statins (57.2% vs 73.9%), RAASi (45.6% vs 59.0%), and OMT combinations including all 4 medications (17.5% vs 32.5%). These differences remained after multivariable adjustment, particularly for statins (adjusted OR: 0.62; 95% CI: 0.40-0.96) and RAASi (adjusted OR: 0.56; 95% CI: 0.38-0.84). Sex disparities were most pronounced among adults under 50 years, with slower increases in OMT uptake over time among women.
conclusionsFrom 2011 to 2020, women, particularly younger women, remained less likely than men to receive guideline-directed OMT for self-reported IHD. These findings underscore the need for policy and practice interventions to improve equitable treatment in cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.